HUTCHMED (China) (AIM:HCM) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HCM Overzicht aandelen

HUTCHMED (China) Limited, samen met haar dochterondernemingen, ontdekt, ontwikkelt en verkoopt doelgerichte therapeutica en immuuntherapieën voor kanker en immunologische ziekten in Hong Kong en internationaal.

Over het bedrijf

HCM fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 64.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 48.23% per jaar groeien

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

HUTCHMED (China) Limited Concurrenten

Dechra Pharmaceuticals

LSE:DPH

UK£4.4b

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

Indivior

LSE:INDV

UK£1.0b

Alliance Pharma

AIM:APH

UK£230.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor HUTCHMED (China)
Historische aandelenkoersen
Huidige aandelenkoers	UK£3.10
52 Week Hoogtepunt	UK£3.53
52 Week Laag	UK£1.90
Bèta	0.76
11 maand verandering	18.32%
3 maanden verandering	16.98%
1 Jaar Verandering	14.39%
33 jaar verandering	-36.61%
5 jaar verandering	13.97%
Verandering sinds IPO	1,137.52%

Recent nieuws en updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02

Recent updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

Rendement voor aandeelhouders

	HCM	GB Pharmaceuticals	GB Markt
7D	8.8%	-0.7%	-0.8%
1Y	14.4%	4.5%	9.2%

Rendement versus industrie: HCM overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement 4.6 % opleverde.

Rendement versus markt: HCM overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 9.8 %.

Prijsvolatiliteit

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van HCM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van HCM is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen UK.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	1,970	Wei-Guo Su	www.hutch-med.com

HUTCHMED (China) Limited, samen met haar dochterondernemingen, ontdekt, ontwikkelt en commercialiseert doelgerichte therapeutica en immuuntherapieën voor kanker en immunologische ziekten in Hong Kong en internationaal. Het bedrijf ontwikkelt Savolitinib voor de behandeling van niet-kleincellige longkanker (NSCLC), papillair niercelcarcinoom (RCC) en maagkanker (GC); en Fruquintinib, een remmer voor colorectale kanker (CRC), borstkanker, maagkanker, microsatellietstabiele-CRC endometriumkanker (EMC), NSCLC, RCC, gastro-intestinale, baarmoederhalskanker en solide tumoren. Het ontwikkelt ook Surufatinib, dat wordt gebruikt voor de behandeling van pancreas neuro-endocriene tumor (NET), niet-pancreatische NET, neuro-endocrien carcinoom, SCLC, galwegkanker en solide tumoren; en Sovleplenib dat hematologische kankers en bepaalde chronische immuunziekten behandelt.

HUTCHMED (China) Limited Samenvatting

Hoe verhouden de winst en inkomsten van HUTCHMED (China) zich tot de beurswaarde?
HCM fundamentele statistieken
Marktkapitalisatie	UK£2.65b
Inkomsten(TTM)	-UK£31.97m
Inkomsten(TTM)	UK£465.32m

5.7x

P/S-verhouding

-82.9x

Koers/Winstverhouding

Is HCM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HCM resultatenrekening (TTM)
Inkomsten	US$610.81m
Kosten van inkomsten	US$658.26m
Brutowinst	-US$47.45m
Overige uitgaven	-US$5.48m
Inkomsten	-US$41.97m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.049
Brutomarge	-7.77%
Nettowinstmarge	-6.87%
Schuld/Eigen Vermogen Verhouding	10.9%

Hoe presteerde HCM op de lange termijn?

Bekijk historische prestaties en vergelijking

HCM Overzicht aandelen

Beloningen

Risicoanalyse

HUTCHMED (China) Limited Concurrenten

LSE:DPH

UK£4.4b

LSE:HIK

UK£4.2b

LSE:INDV

UK£1.0b

AIM:APH

UK£230.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Recent updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Investor sentiment improves as stock rises 16%

Consensus EPS estimates upgraded to US$0.11 loss

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet